: The prognosis of pancreatic ductal adenocarcinoma is still the worst among solid tumors. In this review, a panel of experts addressed the main unanswered questions about the clinical management of this disease, with the aim of providing practical decision support for physicians. On the basis of the evidence available from the literature, the main topics concerning pancreatic cancer are discussed: the diagnosis, as the need for a pathological characterization and the role for germ-line and somatic molecular profiling; the therapeutic management of resectable disease, as the role of upfront surgery or neoadjuvant chemotherapy, the post-operative restaging and the optimal timing foradjuvant chemotherapy, the management of the borderline resectable and locally advanced disease; the metastatic disease and the role of surgery for the management of patients with isolated metastasis and the use of biomarkers of metastatic potential; the role of supportive care and the healthcare management of pancreatic ductal adenocarcinoma.

Evolving pancreatic cancer treatment: From diagnosis to healthcare management

Milella, Michele;Bassi, Claudio;Cavaliere, Alessandro;Malleo, Giuseppe;
2022-01-01

Abstract

: The prognosis of pancreatic ductal adenocarcinoma is still the worst among solid tumors. In this review, a panel of experts addressed the main unanswered questions about the clinical management of this disease, with the aim of providing practical decision support for physicians. On the basis of the evidence available from the literature, the main topics concerning pancreatic cancer are discussed: the diagnosis, as the need for a pathological characterization and the role for germ-line and somatic molecular profiling; the therapeutic management of resectable disease, as the role of upfront surgery or neoadjuvant chemotherapy, the post-operative restaging and the optimal timing foradjuvant chemotherapy, the management of the borderline resectable and locally advanced disease; the metastatic disease and the role of surgery for the management of patients with isolated metastasis and the use of biomarkers of metastatic potential; the role of supportive care and the healthcare management of pancreatic ductal adenocarcinoma.
Adjuvant chemotherapy
Borderline Resectable pancreatic cancer
Healthcare management
Locally advanced pancreatic cancer
Neoadjuvant chemotherapy
Pancreatic ductal adenocarcinoma
Patient-reported outcomes
Delivery of Health Care
Humans
Neoadjuvant Therapy
Prognosis
Carcinoma, Pancreatic Ductal
Pancreatic Neoplasms
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842821003589-main.pdf

solo utenti autorizzati

Tipologia: Versione dell'editore
Licenza: Accesso ristretto
Dimensione 840.12 kB
Formato Adobe PDF
840.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1063640
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact